|
1 Freeman AF，Shulman ST. Recent developments in Kawasaki disease. Curr Opinion Infect Dis，2001，14(3)：357-361.
|
|
2 Kato H，Sugimura T，Akagi T，et al. Long-term consequences ofKawasaki disease. A 10- to 21-year follow-up study of 594patients. Circulation, 1996, 94(6)：1379-1385.
|
|
3 Matsubara T, Mason W, Kashani IA, et al. Gastrointestinal hemorrhage complicating aspirin therapy in acute Kawasaki disease. J Pediatr, 1996，128(5 Pt 1):701-703.
|
|
4 Furusho K，Kamiya T，Nakano H，et al. High-dose intravenousgammaglobulin for Kawasaki disease. Lancet, 1984，2(8411):1055-1058.
|
|
5 Nagashima M，Matsushima M，Matsuoka H，et al. High-dosegammaglobulin therapy for Kawasaki disease. J Pediatr, 1987，110(5):710-712.
|
|
6 Durongpisitkul K，Gururaj VJ，Park JM，et al. The prevention of coronary artery aneurysm in Kawasaki disease：A meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics，1995，96(6)：1057-1061.
|
|
7 Muta H, Ishii M，Egami K，et al. Early intravenous gamma¬globulin treatment for Kawasaki disease：The nationwide surveys in Japan. J Pediatr, 2004, 144(4):496-499.
|
|
8 Newburger JW，Takahashi MS, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New Engl J Med, 1991，324(23)：1633-1639.
|
|
9 Brogan P，Bose A，Burgner D，et al. Kawasaki disease：An evidence based approach to diagnosis，treatment，and proposals forfuture research. Archiv Dis Childhood, 2002，86(4)：286-290.
|
|
10 Sei-ichiro O，Koichi S. Randomized-prospective study of a single infusion of 1 g/kg gammaglobulin for reducing a total dose of gammaglobulin in kawasaki disease treatment. Inter Pediatr Res Found, 2003，53(1):181.
|
|
11 Sung RYT，Sol LY. Treatment of Kawasaki disease with intravenous immunoglobulin：A comparison of the 2 g/kg regime with a 1 g/kg flexible regime. Inter Pediatr Res Found，2003，53(1)：180.
|
|
12 Kato H，Koike S，Yokoyama T. Kawasaki disease：Effect oftreatment on coronary artery involvement. Pediatrics, 1979，63(2):175-179.
|
|
13 梁翊常.川崎病的冠状动脉损伤.中国实用儿科杂志，1999，14(3)：132-133.
|
|
14 邢艳林，王金元.对川崎病丙种球蛋白治疗无效的高危因素分析.小儿急救医学，2004,11(4): 243-244.
|
|
15 Fukunishi M，Kikkawa M，Hamana K. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr, 2000，137(2):172-176.
|
|
16 Burns JC, Capparelli EV，Brown JA, et al. Intravenous gamma¬globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J，1998,17(12)：1144-1148.
|
|
17 Brogan PA, Bose A, Burgner D, et al. Kawasaki disease：An evidence based approach to diagnosis，treatment，and proposals for future research. Archiv Dis in Childhood, 2002，86(4)：286-290.
|
|
18 Dale RC, Saleem MA, Daw SL，et al. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr, 2000, 137(5)：723-726.
|
|
19 Hashino K, Ishii M, Iemura M, et al. Re-treatment for immune globulin-resistant Kawasaki disease：A comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int，2001，43(3)：211-217.
|
|
20 Raman V, Kim J, Sharkey A, et al. Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr Infect Dis J, 2001，20(6)：635-637.
|
|
21 Zaitsu M，Hamasaki Y，Tashiro K, et al. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis, 2000，181(3):1101-1109.
|
|
22 Burns JC, Mason W，Hauger S，et al. Infliximab treatment forrefractory Kawasaki syndrome. J Pediatr, 2005，146 (5): 662-667.
|
|
23 Villain E，Kachaner J，Sidi D，et al. Essai de prevention des anevrismes coronaires de la maladie de Kawasaki par echanges plasmatiques ou perfusion d'immunoglobulines. Arch Fr Pediatr,1987，44(2)：79-83.
|
|
24 Imagawa T，Mori M，Miyamae T，et al. Plasma exchange forrefractory Kawasaki disease. Eur J Pediatr, 2004, 163(4-5):263-264.
|